Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 29300-155

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 29300-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 01

Chemical structure of Alfuzosin hydrochloride, showing the molecular arrangement of the active ingredient used in oral extended-release tablets.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 02

A line graph showing Alfuzosin plasma concentration (ng/mL) over 24 hours comparing fed and fasted conditions. The y-axis represents plasma concentration from 0 to 14 ng/mL, and the x-axis shows time from 0 to 24 hours. Two curves with error bars illustrate higher concentrations under fed conditions compared to fasted, peaking around 8 hours before declining.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 03

A line graph showing mean change over 84 days of treatment comparing Alfuzosin hydrochloride extended-release tablets (10 mg) against placebo. The x-axis represents days of treatment (0, 28, 56, 84) and the y-axis shows mean change levels, with the Alfuzosin group demonstrating a greater decrease than placebo over time, with significant difference indicated at day 84 (p < 0.001).*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 04

Line graph showing mean change over days of treatment for Placebo and Alfuzosin hydrochloride extended-release tablets groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis represents mean change. Alfuzosin hydrochloride shows greater mean change reduction compared to placebo, with statistical significance noted at day 84 (p < 0.01).*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 05

A line graph comparing mean change over days of treatment (0 to 84) between placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151). The graph shows a greater mean decrease for Alfuzosin hydrochloride over time, with a statistically significant difference indicated at day 84 (p < 0.01).*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 06

A line graph comparing the mean change in a measurement (ml/s) over days of treatment (0, 28, 56, 84) between placebo and Alfuzosin hydrochloride extended-release tablets. Alfuzosin shows a higher mean change sustained from day 28 to day 84 compared to placebo, with statistical significance indicated at day 84 (p < 0.001).*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 07

A line graph comparing the mean change in mL/s over days of treatment for Alfuzosin hydrochloride extended-release tablets (N=136) versus placebo (N=147). The graph shows higher mean change values for Alfuzosin hydrochloride over 84 days, with significant difference marked at day 84 (p < 0.05). The x-axis represents days of treatment (0 to 84), and the y-axis represents mean change in mL/s (0 to 3).*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 08

A line graph depicting mean change in mL/s over days of treatment (0, 14, 28, 56, 84) comparing placebo (N=150) and alfuzosin hydrochloride extended-release tablets (N=151). Both groups show an initial increase, with alfuzosin consistently higher. The chart notes no statistically significant difference (NS p > 0.05) at day 84.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 09

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 10

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 11

Label for Alfuzosin Hydrochloride Extended-Release Tablets, USP 10 mg, oral tablets, containing 30 tablets per package. The label includes dosing and storage instructions, manufacturer details as Unichem Laboratories Ltd. in India, and distributor Unichem Pharmaceuticals (USA), Inc. The NDC number is 29300-155-13.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.